InBody Co.,Ltd (KOSDAQ:041830)
32,750
+250 (0.77%)
At close: Dec 30, 2025
InBody Co.,Ltd Revenue
InBody Co.,Ltd had revenue of 59.80B KRW in the quarter ending September 30, 2025, with 17.90% growth. This brings the company's revenue in the last twelve months to 226.62B, up 18.46% year-over-year. In the year 2024, InBody Co.,Ltd had annual revenue of 204.46B with 20.03% growth.
Revenue (ttm)
226.62B
Revenue Growth
+18.46%
P/S Ratio
1.76
Revenue / Employee
662.64M
Employees
342
Market Cap
399.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 204.46B | 34.11B | 20.03% |
| Dec 31, 2023 | 170.35B | 10.35B | 6.47% |
| Dec 31, 2022 | 160.00B | 22.17B | 16.08% |
| Dec 31, 2021 | 137.84B | 30.71B | 28.67% |
| Dec 31, 2020 | 107.12B | -9.94B | -8.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |